皮肌炎中自身抗体表型与羟氯喹皮肤不良反应的关联
该回顾性队列研究纳入111例开始接受羟氯喹治疗的成人皮肌炎患者,23例(20.7%)在治疗4周内出现羟氯喹相关皮疹。抗SAE-1/2抗体阳性者皮疹发生率50.0%(7/14),抗MDA-5抗体阳性者无皮疹发生(0/15);校正后抗SAE-1/2抗体与皮疹显著正相关(OR 8.43),抗MDA-5抗体与皮疹显著负相关(OR 0.06)。
要点
- 111例成人皮肌炎患者中23例(20.7%)出现羟氯喹相关皮疹。
- 抗SAE-1/2抗体阳性者皮疹发生率50.0%(7/14),无该抗体者为16.5%(16/97)。
- 抗MDA-5抗体阳性者无皮疹(0/15),无该抗体者为24.0%(23/96)。
核心结论
- 在美国皮肌炎队列中,羟氯喹相关皮肤不良反应相对常见。
- 数据提示皮肌炎不同自身抗体亚群之间存在病理生理差异。
研究设计与样本
- 回顾性队列研究,在一家三级学术转诊中心的皮肤科门诊开展。
- 纳入1990年7月1日至2016年9月13日期间开始接受羟氯喹治疗的111例年龄>18岁成人皮肌炎患者。
- 羟氯喹相关皮疹定义为治疗最初4周内出现皮疹且停用羟氯喹后消退。
主要发现
- 111例患者中23例(20.7%)出现羟氯喹相关皮疹,其中20例(87.0%)为女性,诊断时平均(SD)年龄49(14)岁。
- 抗SAE-1/2抗体阳性者皮疹发生率50.0%(7/14),无该抗体者为16.5%(16/97)。
- 抗MDA-5抗体阳性者皮疹发生率0%(0/15),无该抗体者为24.0%(23/96)。
- 校正年龄、种族/民族、性别、无肌病状态、抗Ro52状态及皮肌炎相关癌症后,抗SAE-1/2抗体与皮疹显著正相关(OR 8.43;95%CI 1.98-49.19;P=0.003),抗MDA-5抗体与皮疹显著负相关(OR 0.06;95%CI 0.0004-0.52;P=0.006)。
- 其他自身抗体与羟氯喹相关皮疹无显著正相关或负相关。
关键数值与推荐
- 抗SAE-1/2抗体阳性者皮疹发生率50.0%(7/14),无该抗体者16.5%(16/97)。
- 抗MDA-5抗体阳性者皮疹发生率0%(0/15),无该抗体者24.0%(23/96)。
- 抗SAE-1/2抗体与皮疹的校正OR为8.43(95%CI 1.98-49.19;P=0.003)。
- 抗MDA-5抗体与皮疹的校正OR为0.06(95%CI 0.0004-0.52;P=0.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hydroxychloroquine sulfate is a commonly used medication for patients with dermatomyositis and has been associated with a uniquely elevated risk of adverse cutaneous reactions in this population. No studies to date have examined whether certain subsets of patients with dermatomyositis are at increased risk of experiencing a hydroxychloroquine-associated skin eruption. OBJECTIVE: To identify disease features that increase the risk of hydroxychloroquine-associated skin eruption in adults with dermatomyositis. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted in the outpatient dermatology clinic at a tertiary academic referral center. All adults with dermatomyositis (age >18 years) who started receiving hydroxychloroquine between July 1, 1990, and September 13, 2016, were eligible for the analysis. Patients were considered to have a hydroxychloroquine-associated skin eruption if a skin eruption had developed within their first 4 weeks of treatment and resolved with discontinuation of hydroxychloroquine therapy. EXPOSURES: One or more doses of hydroxychloroquine. MAIN OUTCOMES AND MEASURES: The associations between autoantibodies (against transcription intermediary factor 1γ [TIF-1γ], nucleosome-remodeling deacetylase complex [Mi-2], nuclear matrix protein [NXP-2], small ubiquitinlike modifier 1 activating enzyme [SAE-1/2], melanoma differentiation-associated gene 5 [MDA-5], histidyl-transfer RNA synthetase [Jo-1], Ku, and signal recognition particles) and cutaneous adverse reactions to hydroxychloroquine in patients with dermatomyositis. RESULTS: A total of 111 patients met the inclusion criteria, and 23 (20.7%) developed a hydroxychloroquine-associated skin eruption (20 [87.0%] were women with a mean [SD] age of 49 [14] years at diagnosis). Skin eruptions were approximately 3 times more common in patients with anti-SAE-1/2 autoantibodies (7 of 14 [50.0%]) compared with those without the autoantibody (16 of 97 [16.5%]). In contrast, none of 15 patients with anti-MDA-5 autoantibodies had a skin eruption vs 23 of 96 (24.0%) of those without the autoantibody. In exact logistic regressions adjusted for age, race/ethnicity, sex, amyopathic status, anti-Ro52 status, and dermatomyositis-associated cancer, the presence of anti-SAE-1/2 autoantibodies was significantly associated with a hydroxychloroquine-associated skin eruption (odds ratio [OR], 8.43; 95% CI, 1.98-49.19; P = .003) and presence of anti-MDA-5 autoantibodies was significantly negatively associated with a hydroxychloroquine-associated skin eruption (OR, 0.06; 95% CI, 0.0004-0.52; P = .006). No other autoantibodies were significantly positively or negatively associated with a hydroxychloroquine-associated skin eruption. CONCLUSIONS AND RELEVANCE: Adverse skin reactions to hydroxychloroquine are relatively common in a US cohort of patients with dermatomyositis. Our data suggest that pathophysiologic differences exist between autoantibody subsets in dermatomyositis.
引用
- Wolstencroft PW, Casciola-Rosen L, Fiorentino DF, et al. Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis. JAMA Dermatol. 2018. PMID: 30140893. doi:10.1001/jamadermatol.2018.2549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。